CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris
European drug regulator has recommended Ultomiris for use in children and adolescents with PNH
Read More
Tag: PNH
Novartis’ oral therapy iptacopan shows promise in PNH
Majority of patients were transfusion-free through 12 weeks of study, according to the new data
Read More
NHS patients with rare blood disorders gain access to Ultomiris
Around 270 people with PNH and 160 people with aHUS will be eligible for the new treatment
Read More
NICE recommends Alexion’s PNH treatment Ultomiris
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
Read More
EU approval for Alexion’s PNH drug Ultomiris
The decision allows use of the drug in patients with haemolysis with clinical symptoms indicative of high disease activity
Read More
Alexion gears up to file new blood disorder drug
Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
